Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Travere Therapeutics Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and delivering therapies to people living with rare kidney, liver, and metabolic diseases. The Company’s products are Thiola and Thiola EC (tiopronin tablets) used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company has received approval of FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI, a once-daily, oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin 1 and angiotensin-II) and is a non-immunosuppressive therapy approved for the treatment of this condition. FILSPARI (sparsentan) is a dual endothelin angiotensin receptor antagonist (DEARA). Sparsentan has been granted Orphan Drug Designation for the treatment of IgAN in the United States and Europe.
TVTX - Travere Therapeutics Inc
Report
There was a problem reporting this post.
Block Member?
Please confirm you want to block this member.
You will no longer be able to:
See blocked member's posts
Mention this member in posts
Please allow a few minutes for this process to complete.